Navigation Links
PEGylation in Medical News

FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform

Cimzia(R) marks the first FDA approval of a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody SAN FRANCISCO, April 23 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved UCB's Cimzia(R) (certolizumab pegol) for reducing the signs and sy...

Nektar's Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York

Nektar Highlights Innovative New Product Development in the Areas of Oncology, Anti-Infectives, CNS and Pain Therapies NEW YORK, Nov. 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) showcased its two industry-leading Pulmonary and PEGylation technology platforms a...

Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis

...ered trademark of UCB PHARMA S.A. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for part...

Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston

...for replay until June 10, 2009. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for par...

NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR

...mo r docetaxel exposure." About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for part...

Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors

...enograft models, respectively. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for par...

Cell transplantation and diabetes: New sites, new devices

... are issues with injecting encapsulated cells into the liver. Finally, the research team suggested decreasing capsule size to nano-scale and combining pegylation coating of capsules with a layer of poly(ethylene) glycol molecules with low-dose immunosuppression to improve engraftment and long-term function. C...

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results

...y's website at http://www.nektar.com . About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and conjugate chemistry technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, whi...

Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets

... the conclusion of the conference call. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and conjugate chemistry technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, whi...

Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008

...e of N-terminally blocked proteins. MALDI-TDS is available on Bruker's top-of-the line ultraflex™ III TOF/TOF system for the characterization of pegylation sites and other protein modifications of vital importance in fields such as recombinant protein production, biologics drug development and quality con...
PEGylation in Medical Technology

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...ith a passcode of 26851386. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for part...

Another LNA-based RNA Inhibitor Enters Clinical Trials

...ams utilize several cutting-edge approaches, including its industry-leading pegylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon's pegylation technology was used to develop two of its products, Oncaspar and Adagen, an...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

...rticipant Passcode: 44161634 About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for par...

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

...eduction of tumor volume that could potentially improve patient survival. pegylation refers to the covalent attachment of polyethylene glycol to a molecule, usu...ave a prolonged circulatory time due to a reduction in renal clearance. The pegylation of rHuPH20 increases its plasma half-life to greater than 24 hours compared...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

... "The promise of NKTR-102 and our small molecule pegylation platform is capturing a great deal of attention am... lung cancers. By applying Nektar's small molecule pegylation technology to irinotecan, NKTR-102 may prove to be...as compared to treatment with irinotecan. Nektar pegylation technology can enhance the properties of therapeut...

Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)

...ndustry-leading PEGylation and pulmonary drug development platforms. Nektar pegylation technology has enabled eight approved products for partners, which include ...technology companies. Nektar also develops its own products by applying its pegylation and pulmonary technology platforms to existing medicines with the objective...

Amikacin Inhale Shows Promising Results in Phase II Study

...ndustry-leading PEGylation and pulmonary drug development platforms. Nektar pegylation and pulmonary technology, expertise, manufacturing capabilities have enable...panies. Nektar also develops its own products by applying its pulmonary and pegylation technology platforms to existing medicines with the objective to enhance pe...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

... Nektar's Technology Enables First-Ever pegylation of a Small Molecule with Demonst...udy also demonstrates that Nektar's small molecule pegylation technology produced an increase in SN38 exposure t...e at Scottsdale Healthcare. Nektar's proprietary pegylation technology can enhance the properties of therapeut...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

...ced constipation. Nektar's advanced small molecule pegylation technology has been shown to reduce NKTR-118's pen...nal drug combines Nektar's advanced small molecule pegylation technology platform with naloxol, a derivative of ...st common opioid-related side effects.(2) Nektar pegylation Platform Nektar...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

...developed using Nektar's innovative small molecule pegylation technology platform. NKTR-102 is currently in a Ph...egimens," said Tim Riley, Ph.D., Vice President of pegylation Research at Nektar. "These data reinforce our conf... lung cancers. By applying Nektar's small molecule pegylation technology to irinotecan, NKTR-102 may prove to be...
PEGylation in Biological News

Versartis presents positive preclinical data on 2 product candidates at ENDO 09

...ciety's Annual Meeting in Washington, DC. Versartis, through a unique licensing agreement with Amunix, Inc., uses the Amunix proprietary recombinant pegylation (rPEG) technology to extend the half-life of established biologics. The preclinical Versartis compounds have the potential for significantly less fre...

Clearance of hepatitis C viral infection after liver transplantation

...ve the life of the patient, Dr Ichikawa decided to introduce the more powerful medicine, PEGylated IFN, in the treatment before liver transplantation. pegylation is a chemical modification incurring higher water-solubility and higher stability to the modified polypeptide medicine. Five weeks after the PEG-IFN t...
PEGylation in Biological Technology

Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit

SAN CARLOS, Calif., May 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that Bharatt Chowrira, Ph.D., J.D. has joined the Company as Chief Operating Officer and Head of the PEGylation Business Unit. His responsibilities include overseeing and managing all aspe...

Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress

SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) highlighted today that its proprietary PEGylation technology is used in the novel therapeutic, Hematide(TM), a synthetic, peptide-based erythropoiesis-stimulating agent that is under development by Takeda...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

...or replay until August 31, 2009. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for part...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

...clusion of the conference call. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for part...

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer

...s board certified in Neurology. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for part...

Nektar Therapeutics Reports First Quarter 2009 Financial Results

...rticipant Passcode: 19053055 About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partne...

Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer

...e cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome About Sopherion Therapeutics, LLC Sopherion Therapeutics, LLC is a privately-held biotechnology ...

Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston

...for replay until April 1, 2009. About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for par...

Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results

...rticipant Passcode: 44161634 About Nektar Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its pegylation and advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partne...

Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients

...e cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome. The results of the SOLTI study further support an ongoing registration trial in patients with metastat...
Other Tags
(Date:12/26/2014)... The Biofeedback Federation of Europe annual ... in Rome, Italy and is hosted by the Salesian ... on a wide variety of topics such as ADHD, ... training in athletes. The scientific program will feature the ... monitoring allows clients to see what is going on ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on ... Pennsylvania for 2014. The awards program, created in 2000, ... kind in the country. The program is a public/private ... Community and Economic Development, the Pennsylvania State Council of ... Penn Business Journal. , Charlie Wilson, Vice ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... 2014 The short film “Color of Honor” ... honor of a true 9/11 hero, Welles Remy Crowther. It ... the 24 hours of Nuremberg International Short Film Festival and ... Actress, screenwriter and director Luciana Lagana plays the ... with her husband, Gregory Graham - Graham plays ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
Other Contents